Fritextsökning
Innehållstyper
-
Lundbeck presenterar första behandlingen mot MSA
Danska läkemedelsbolaget Lundbeck har utvecklat antikroppen amlenetug, som kan innebära den första behandling av multipel systematrofi (MSA).
-
Mastering Urine Microscopy: Techniques for Accurate Disease Detection
Live Webinar on September 25, 2024.
-
Neogap värvar tungt namn inom cellterapi
Bioteknikbolaget Neogap Therapeutics fyller på styrelsen med expertis inom cellterapi i form av professor Jonas Mattsson.
-
The New Precise Magazine is Available Now
Download the new issue.
-
A new life science cluster formed – “We are very strong in talent”
Stockholm and Uppsala’s joint life science cluster aims to be among the best in Europe. Pontus Holm, Life Science Coordinator for Region Stockholm, says the dec...
-
Scale Up Your Image Analysis
ZEISS arivis Hub for accelerated analysis and faster results.
-
ZEISS Insights: Measurement of bone plates and screws
Get free access to technical paper.
-
Medivir CEO on upcoming study: ”It's about working together with others”
Medivir is a small company with a big task: to take its drug candidate, via extensive clinical studies, all the way to a patient group that currently lacks appr...
-
Life science trends 2025 – The economy
Upcoming patent expirations are driving pharmaceutical companies to acquire in 2025. In Sweden, we may be on our way to brighter times and fewer bankruptcies. T...
-
Charged with illegal pharmaceutical sales – alleged earnings of 23 million
For at least five years, two men allegedly carried out illegal sales of pharmaceuticals and supplements, amassing millions. They are now facing charges at Söder...
-
Drug development booms in Medicon Valley
When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on commission for pharmaceutical compani...
-
Digital Temperature Sensors from ZEISS
New Metrology Expert Tip video.
-
New features in ZEISS CALYPSO 2024
ZEISS CALYPSO is your universal software for dimensional metrology applications.
-
Positive EMA Decision for BioArctic's New Drug Candidate
Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).
-
Icelandic pharmaceutical company Alvotech to list on Nasdaq Stockholm
One of Iceland's largest companies, the pharmaceutical firm Alvotech, has announced its intention to list on Nasdaq Stockholm.
-
Final assembly inspection of medical plastics
Technical paper by ZEISS Medical Industry Solutions.
-
Reveal the Structures and Functions of Life
Super-resolution microscopes from ZEISS.
-
The top five most expensive drugs in 2025
New advanced therapeutic medicines are reaching the market, but their price tags remain exceptionally high. This year’s ranking of the most expensive drugs in t...
-
Medical device quality assurance
Recordings from ZEISS Quality Innovation Days.
-
Column: ”Life as a F1 race”
"The F1 car makes several pit stops during a race and during a lifetime the human being may also have to come in several times for maintenance", Björn Ursing wr...
-
Total pipeline of pharmaceutical companies reaches a record high – 22,921 medicines are currently being developed
Despite the difficult economic times, pharmaceutical companies have never developed as many new drugs as now.
-
Cleveland Clinic: Kirurgi gav fler långsiktiga fördelar än GLP-1-läkemedel
Metabol kirurgi minskade riskerna för död, hjärtsjukdom, njursvikt och ögonskador mer än GLP-1-läkemedel under en tioårsperiod. Det enligt en ny studie från Cleveland Clinic i USA....
-
The race between new alzheimer’s drugs Kisunla and Leqembi heats up
Kisunla or Leqembi? The rivalry between Eli Lilly and Bioarctic is intensifying. Where one drug gains approval, the other falls behind. Here's a look at the mar...
-
The scientist behind Novo Nordisk's obesity success: “I never stopped believing in GLP-1”
It took several years of failures in GLP-1 before Lotte Bjerre Knudsen and her colleagues found the right path – but when they did, it was a true breakthrough. ...
BREAKING